Evolent Health price target lowered to $45 from $47 at Canaccord

Canaccord lowered the firm’s price target on Evolent Health to $45 from $47 and keeps a Buy rating on the shares. The firm said they remain encouraged with Evolent’s performance and believe the company sits in a unique position to assist managed care in addressing rising medical costs trends with specialty care management offerings targeting cardiovascular, musculoskeletal, and oncology care.